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Abstract
Background: Neoadjuvant chemoradiation (NCR) prior to resection of extremity soft tissue sarcoma (STS) has been
studied, but data are limited. We present outcomes with NCR using a variety of chemotherapy regimens compared
to neoadjuvant radiation without chemotherapy (NR) and surgery alone (SA).
Methods: We conducted a retrospective chart review of 112 cases.
Results: Treatments included SA (36 patients), NCR (39 patients), and NR (37 patients). NCR did not improve the
rate of margin-negative resections over SA or NR. Loco-regional relapse-free survival, distant metastases-free
survival, and overall survival (OS) were not different among the treatment groups. Patients with relapsed disease
(OR 11.6; p = 0.01), and tumor size greater than 5 cm (OR 9.4; p = 0.01) were more likely to have a loco-regional
recurrence on logistic regression analysis. Significantly increased OS was found among NCR-treated patients with
tumors greater than 5 cm compared to SA (3 year OS 69 vs. 40%; p = 0.03). Wound complication rates were
higher after NCR compared to SA (50 vs. 11%; p = 0.003) but not compared to NR (p = 0.36). Wet desquamation
was the most common adverse event of NCR.
Conclusions: NCR and NR are acceptable strategies for patients with STS. NCR is well-tolerated, but not clearly
superior to NR.
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Background
Extremity soft tissue sarcoma (STS) treatment strategies
gradually have shifted awayf r o ma m p u t a t i o nt o w a r da
limb preservation approach. For most patients with low-
grade extremity STS, (i.e., T1-2, N0, M0) surgical resec-
tion is the primary treatment, followed by adjuvant
radiation for margins less than or equal to 1 centimeter
[1]. For patients with high-grade STS of the extremities
(i.e., Stages II or III), neoadjuvant radiation with or
without chemotherapy often is employed to improve
local control and functional outcome [1].
Experience with neoadjuvant chemoradiation (NCR) in
STS has been reported by several groups. Eilber and col-
leagues published a regimen of intra-arterial doxorubicin
infused over 24-hours for 3 days prior to radiation, fol-
lowed by surgery [2]. Other single agents that have been
studied with pre-operative radiation include ifosfamide
and gemcitabine [3,4]. Multi-agent chemotherapy regi-
mens given pre-operatively with radiation include MAID
(mesna, doxorubicin, ifosfamide and dacarbazine) or
IMAP/MAP (ifosfamide, mitomycin, doxorubicin, and
cisplatin) [5-7]. These strategies have shown promising
results, including 5-year overall survival rates up to 70%
[8-11], 5-year local control rates up to 92% [5] and limb
preservation rates up to 100% [4]. Toxicities of NCR
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require re-operation, and long bone fracture [12].
At Mayo Clinic in Arizona (MCA), the decision to use
NCR, neoadjuvant radiation (NR) or surgery alone (SA)
is based on initial magnetic resonance imaging (MRI)
findings. Patients likely to have narrow resection mar-
gins, with high grade tumors, large tumor size, and an
unfavorable location relative to the neuro-vascular bun-
dles and bone are referred to radiation oncology and
medical oncology for consideration of NR or NCR.
Despite its use, data on outcomes with NCR for Stage II
and III extremity STS are limited. A prospective, rando-
mized trial comparing NCR to NR and SA is needed to
provide more robust knowledge. In the absence of such
information, a retrospective analysis can provide preli-
minary insight and be used for hypothesis generation.
Therefore, we conducted a retrospective analysis of
patients with extremity STS treated at MCA to increase
our understanding of NCR-related outcomes as com-
pared to NR- and SA-treated patients.
Methods
A retrospective chart review was conducted of 112
extremity STS cases treated between January 1, 1998
and December 31, 2009 at MCA. We included patients
greater than 15 years of age with Stage II and III extre-
mity STS as defined by the 2010 7
th Edition American
Joint Committee on Cancer (AJCC) Staging System of
STS. Patients with relapsed extremity STS being treated
with curative intent were included. Non-extremity sar-
comas, low grade (Stage I) extremity STS, and bone/car-
tilage sarcomas were excluded. Patients treated with
post-operative radiation and patients with metastatic or
recurrent disease receiving only palliative treatments
were excluded. The review was approved by the Mayo
Clinic Institutional Review Board.
The following information was recorded: age at diag-
nosis, date of first MCA evaluation, sex, primary disease
site, histology, grade, tumor size and depth (superficial
or deep as defined by the 2010 AJCC Staging System of
STS), margin status, notation of periosteal or nerve
stripping in the operative summary, limb preservation or
amputation, occurrence of wound complications follow-
ing surgery, date of first local recurrence (if any), date of
appearance of distant metastases (if any), any documen-
tation of treatment-related toxicity, and date of death or
last follow-up at MCA. It was not possible to determine
toxicity grading from medical records. Sarcoma treat-
ment was categorized as follows: SA (defined as any
curative-intent surgical procedure performed without
pre- or post-operative chemotherapy or radiation), NCR
(defined as any combination of chemotherapy with
radiation given prior to a curative-intent surgical resec-
tion), or NR (defined as radiation given without
chemotherapy prior to a curative-intent surgical resec-
tion). Patients treated with sequential pre-operative che-
motherapy followed by pre-operative radiation were
included in the NCR group, since historically such ther-
apy has been considered a form of NCR [2,13]. Use of
intra-operative electron radiation therapy (IOERT) or
perioperative brachytherapy was documented.
Surgical margins were recorded as negative (R0 resec-
tion) if the pathology report noted all margins to be free
of tumor microscopically. If tumor extended to the sur-
gical margin microscopically, or if the surgical margin
was less than or equal to 1 mm, the margin was consid-
ered to be positive (R1 resection). It was not possible to
determine pathologic response rates to NCR or NR
from the records. Loco-regional recurrences were
defined as any relapse of sarcoma at the previous surgi-
cal site or in regional lymph nodes. A “wound complica-
tion” was defined as any post-operative wound event
requiring a return to the operating room for an
unplanned additional procedure.
All time-to-failure endpoints were calculated from the
date of first MCA contact. Overall survival (OS) was
defined as death as a result of any cause; time to loco-
regional recurrence was defined as time to date of a
local or regional relapse diagnosis or amputation for any
reason; time to distant metastases was defined as time
to date of discovery of distant metastases, excluding new
primary cancers. Kaplan-Meier methods were used to
estimate OS, loco-regional relapse-free survival (LR-
RFS), and distant metastasis-free survival (DMFS) for
each of the treatment modality received. Contingency
analyses using the Chi-square test of independence were
conducted for different treatment modalities and surgi-
cal outcome, limb preservation, presence or absence of
local recurrence and distant metastases, and presence or
absence of wound complications. Logistic regression
analyses were performed to determine factors associated
with amputation for relapsed disease, as well as factors
associated with a greater likelihood of wound complica-
tions. Logistic regression analysis also was conducted to
determine factors associated with loco-regional recur-
rence. SA patients who were treated primarily with
amputation were excluded from the analysis of LR-RFS
and wound complications because of potential imbal-
ances among this sub-group compared to the majority
of patients treated with limb-preservation intent.
Results
Patient population
A total of 112 Stage II and III extremity STS cases were
identified. Table 1 lists patient demographics. The med-
ian follow-up was 22.1 months (range 2.5 to 96.4
months). For SA, median follow-up was 26.6 months
(range = 2.5 to 96.4 months); for NCR, 18.4 months
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(range = 3.0 to 90.9 months). A majority of patients
(79%) had lower extremity involvement, but there were
no significant differences observed between disease site
and treatment type. The median tumor size for the
cohort was 7.9 cm (range = 0.4 cm - 29.6 cm). The
median size of SA-treated tumors was significantly smal-
ler than NCR-treated tumors (p = 0.003), but not signif-
icantly different from NR-treated tumors (p = 0.08).
Tumors greater than 5 cm were treated typically with
either NCR or NR (59 of 72 tumors, 82%), whereas only
4 0 %o ft u m o r su n d e r5c mr e c e i v e dN C Ro rN R( 1 2o f
30). Patients with recurrent disease did not have a sig-
nificant difference in median tumor size compared to
patients with primary disease (p = 0.32).
Treatment
Treatments included: SA, 36 patients; NCR, 39 patients;
and NR, 37 patients. One patient each in the NCR and
NR group did not undergo surgery, due to the discovery
of distant metastatic disease prior to surgery. NCR and
NR use increased significantly after 2004, with 87% and
57% of NCR- and NR-treated patients having received
therapy after 2004, respectively, compared to 69% of
SA-treated patients who were treated prior to 2004 (p <
0.001). Patients with an anticipated marginal resection
were selected for pre-operative therapy. Chemotherapy
was utilized in a subset of these patients based on a
multidisciplinary assessment of the tumor status,
planned surgical procedure, co-morbidities, and perfor-
mance status. When eligible, patients were enrolled on
prospective trials using NCR. NCR strategies included
sequential doxorubicin and ifosfamide followed by radia-
tion (n = 1); sequential MAID followed by radiation (n
= 1); sequential MAID followed by weekly cisplatin with
radiation (n = 3); ifosfamide, mitomycin, doxorubicin
and cisplatin with radiation (n = 7); gemcitabine plus
docetaxel with radiation (n = 1); mitomycin, doxorubicin
and cisplatin (without ifosfamide) with radiation (n = 1).
A regimen of cisplatin weekly with radiation (n = 20)
was typically used as the NCR regimen for patients trea-
ted off-protocol. This regimen was selected for its radio-
sensitization properties, for its limited acute toxicity,
and its relative ease of standardization. No chemother-
apy-related information was available for 5 NCR-treated
patients because they received chemotherapy elsewhere
and returned to MCA for surgery only.
The median external beam irradiation (EBRT) dose
was 50.4 Gy in 28 fractions (range 25.2 Gy in 14 frac-
tions to 54 Gy in 30 fractions). All patients were treated
on linear accelerators with photon beam energies
between 6-18MV using standard once-daily fractionation
sizes of 1.8-2.0 Gy. Most of the patients (n = 58) were
treated using three-dimensional conformal radiation
techniques, but, more recently, intensity modulated
radiation therapy (IMRT) was used for selected patients
(n = 10). Details of radiation therapy planning were not
available for 8 patients treated at outside facilities. No
significant differences in the use of IOERT versus perio-
perative brachytherapy were observed between the NCR
and NR groups; no SA patients received IOERT or peri-
operative brachytherapy. There were no significant dif-
ferences in use of IOERT or brachytherapy with regard
to patient age or sex. No significant difference in
Table 1 Characteristics of 112 high-grade, Stage II and III
soft-tissue sarcoma cases
CHARACTERISTIC NCR NR SA P
All 39 37 36
Sex/
Male 19 22 23 0.39
Female 20 15 13
Grade*
2 3 5 8 0.08
31 7 7 1 0
41 6 2 1 1 3
Age (years)
Median (range) 58 (17-88) 71 (32-93) 54.5 (18-86) 0.03
Anatomic site
Upper extremity 8 7 9 0.81
Lower extremity 31 30 27
Histology
Leiomyosarcoma 3 3 4
Liposarcoma 4 10 4
MFH 4 9 10 0.09
Myxofibrosarcoma 12 8 2
Sarcoma NOS 5 2 1
Other 11
a 5
b 15
c
Tumor size (cm)
d
Median (range) 10.6 (0.9-29.6) 8 (2.7-25) 4 (0.4-25) 0.01
<5 cm 4 9 19 0.0002
5-10 cm 14 13 6
>10 cm 20 11 6
Primary disease 37 31 23 0.002
Relapsed disease 2 6 13
NCR, neoadjuvant chemoradiation; NR, neoadjuvant radiation alone; SA,
surgery alone; MFH, malignant fibrous histiocytoma; NOS, not otherwise
specified; cm, centimeters.
*: Grade data missing on 3 NCR, 4 NR and 5 SA-treated patients.
a: synovial sarcoma (n = 5); epithelioid sarcoma (n = 2); myxoid liposarcoma (n
= 1); malignant peripheral nerve sheath tumor (n = 1); extraskeletal myxoid
chondrosarcoma (n = 1); sclerosing epithelioid fibrosarcoma (n = 1).
b: synovial sarcoma (n = 1); myxoid liposarcoma (n = 2); malignant peripheral
nerve sheath tumor (n = 1); clear cell sarcoma of soft tissue (n = 1).
c: synovial sarcoma (n = 4); epithelioid hemangiosarcoma (n = 1); epithelioid
sarcoma (n = 1); myxoid liposarcoma (n = 1); malignant peripheral nerve
sheath tumor (n = 2); mixed histologies (n = 1); clear cell sarcoma of soft
tissue (n = 2); adult fibrosarcoma (n = 1); mesenchymal chondrosarcoma (n =
1); angiosarcoma (n = 1).
d: Does not total 112 due to missing tumor size data for 10 patients.
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and perioperative brachytherapy groups (p = 0.52).
Surgical outcome
Among patients undergoing limb preservation surgery,
R0 resections were achieved in 81 patients (88%). R1
resections occurred in 11 patients (12%). As noted, 2
patients did not undergo resection due to discovery of
distant metastatic disease prior to surgery. In the limb
preservation group, R0 resections were achieved in 91%,
86% and 86% of NCR, NR, and SA-treated patients,
respectively. As shown in Table 2, no significant differ-
ences in R0 resection rate could be detected between
NR and SA (p = 0.95), NCR and SA (p = 0.55), or NCR
and NR (p = 0.45). Periosteal or nerve stripping was
performed in 25 patients undergoing limb preservation
s u r g e r y( S A ,2p a t i e n t s ;N C R ,1 7p a t i e n t s ;N R ,6
patients). Patients treated with NCR or NR were signifi-
cantly more likely to have periosteal or nerve stripping
performed compared to SA-treated patients (p = 0.01).
Of the 112 patients analyzed, 18 patients had a limb
amputation (16%). The median tumor size among these
patients was 6.1 cm (range 0.8-18.5 cm) compared to
7.9 cm (range 0.4-29.6 cm) among patients with limb
preservation (p = 0.45). Among SA-treated patients, 14
patients (39%) had a limb amputation, 6 of whom had
tumors larger than 5 cm. Limb amputation occurred in
3 NCR-treated patients (8%), all with tumors larger than
5 cm. In the NR group, 1 patient (3%) had a limb ampu-
tation, with a tumor of 5.5 cm. There was no significant
difference in the limb amputation rate between NCR-
treated and NR-treated patients (p = 0.32). Patients pre-
senting with recurrent disease were significantly more
likely to have limb amputation than patients with pri-
mary disease (43 vs. 10%; p = 0.001). Among patients
treated for recurrent disease, all limb amputations
occurred in the SA group compared to no amputations
for patients treated with NCR or NR (p = 0.002). Logis-
tic regression analysis of patients undergoing amputa-
tion for recurrent disease showed that these patients
w e r en o tm o r el i k e l yt oh a v er e c e i v e dp r i o rc h e m o t h e r -
apy or radiation than patients with recurrent disease
receiving limb preservation (p = 0.77).
Local Recurrence
Among patients treated with limb-preservation intent,
loco-regional recurrences occurred in 12 patients, 4 in
each treatment group. At 3 years, freedom from local
recurrence was 84%, 88%, and 96% for SA, NR, and
NCR respectively (Figure 1; p = 0.88). Logistic regres-
sion analysis of factors associated with loco-regional
recurrence found no association between age at diagno-
sis (p = 0.72) or tumor site (upper extremity vs. lower
extremity; p = 0.2) and recurrence risk. Patients present-
ing with recurrent disease (OR 11.6; p = 0.01) and
tumor size greater than 5 cm (OR 9.4; p = 0.01) were
more likely to have a loco-regional recurrence on logis-
tic regression analysis. None of the ten patients treated
with IMRT have developed a local recurrence, but any
possible differences in local control based on radiation
technique did not reach statistical significance (p =
0.43).
Distant Metastases
Metastatic disease developed in 30 patients. Three-year
DMFS was 83%, 68%, and 58% for patients treated with
SA, NR, and NCR, respectively, but these were not sta-
tistically significant differences (Figure 2; p = 0.27).
DMFS was significantly inferior at 3 years for patients
treated with SA for recurrent disease (60%) compared to
patients treated with SA for primary disease (94%; Fig-
ure 3; p = 0.03). In contrast, no differences in DMFS for
patients with relapsed or primary disease treated with
NCR or NR could be found.
Overall survival
The median OS was 54.7 months (95% CI; range 41.6 to
96.4 months). No significant differences in OS were
observed among the treatment groups (Figure 4). Three-
year OS was 59%, 67%, and 73% for SA, NR, and NCR,
respectively (p = 0.58). For patients with tumors greater
than 5 cm, superior OS was observed for patients trea-
ted with NCR versus SA (3-year OS 69 vs. 40%; p =
0.03; Figure 5). OS also appeared improved for patients
with tumors greater than 5 cm treated with NR versus
SA (3-year OS 63 vs. 40%; p = 0.02; Figure 5). There
was no difference in OS among patients with tumors
greater than 5 cm treated with NCR compared to NR (p
=0 . 5 7 ) .T a b l e3s u m m a r i z e st h eL R - R F S ,D M F S ,O S ,
and limb preservation rates by treatment modality, with
an additional summary of these outcomes by primary or
recurrent disease status.
Toxicity and wound complications
Any-toxicity recorded was significantly higher among
NCR-treated patients (21 of 39 patients, 54%) compared
to NR-treated patients (10 of 37 patients, 27%; p =
0.02). No toxicity was documented among SA-treated
Table 2 Outcomes of surgical resections among 92 high-
grade, Stage II and III soft-tissue sarcoma cases treated
with limb preservation
RESECTION TYPE NCR NR SA
R0 32 30 19
R1 3 5 3
p = 0.55 NCR-SA; p = 0.45 NCR-NR; p = 0.95 NR-SA
NCR, neoadjuvant chemoradiation; NR, neoadjuvant radiation alone; SA,
surgery alone; R0, surgical resection with microscopically negative margins;
R1, surgical resection with margins involved microscopically.
Curtis et al. Radiation Oncology 2011, 6:91
http://www.ro-journal.com/content/6/1/91
Page 4 of 11patients, significantly less when compared to toxicity
among NCR-treated patients (p < 0.0001). The most
common toxicity among NCR-treated patients was wet
desquamation in the EBRT field and gastrointestinal
toxicity (nausea) from chemotherapy, each in 5 patients.
Wet desquamation occurred in 4 patients treated with
NR. Other toxicities observed in NCR-treated patients
included myelosuppression (n = 2), electrolyte imbal-
ance (n = 1), elevated liver biochemistries (n = 1), ifosfa-
mide-related encephalopathy (n = 1), and venous
thromboembolism (n = 1). No long term complications
were documented.
Wound complications occurred in 19 of 38 (50%)
NCR-treated patients (1 had limb amputation), 15 of 36
(42%) NR-treated patients, and 4 of 36 (11%) SA-treated
patients (1 had limb amputation). Excluding patients
treated with limb amputation, the rate of wound com-
plications was significantly higher among the NCR-trea-
t e dg r o u pc o m p a r e dt oS A( p=0 . 0 0 3 ;T a b l e4 ) .I ta l s o
was higher among the NR-treated group compared to
SA (p = 0.02). Wound complication rates were not sig-
nificantly different between NR and NCR groups for
patients treated with limb preservation (p = 0.36). The
majority of wound complications occurred among lower
extremity tumors in each group (34 of 38 total wound
complications). Significantly more limb-preservation
patients who were treated with NCR and IOERT/perio-
perative brachytherapy had wound complications (16 of
30 patients, 53%) compared to NR-treated patients trea-
ted with IOERT/perioperative brachytherapy (11 of 25
patients, 44%, p = 0.009). However, using logistic regres-
sion analysis, no significant associations were found
between the incidence of wound complications and the
use of NCR or NR (OR 3.39; p = 0.21), use of IOERT or
perioperative brachytherapy (OR 4.61; p = 0.21), or
tumor size (OR 1.06; p = 0.37; Table 5).
Discussion
The primary treatment for Stage II and III extremity
STS is typically surgery combined with pre- or post-
operative radiation. Chemotherapy remains a controver-
sial component of management. Based on the results of
this study, NCR does not appear to improve outcomes
compared to NR.
Patients at risk 
Time 
(mos) 
10  20  30  40  50  60  70  80  90 
SA  18  17  10  8  7  5  4  3  2 
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Figure 1 Loco-regional relapse free survival. Kaplan-Meier plot of 92 Stage II and III extremity soft-tissue sarcoma patients treated with limb-
preservation by treatment modality (surgery alone, neoadjuvant chemoradiation, or neoadjuvant radiation alone).
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Page 5 of 11Neither NCR nor NR appeared to improve LR-RFS
compared to SA. Previous phase III randomized trials
have shown pre- and post-operative EBRT [14-19] and
peri-operative brachytherapy [20-22] improve LR-RFS
compared to SA. Our findings are likely impacted by
the high degree of pre-treatment patient selection. Fac-
tors such as tumor grade, large size, and location rela-
tive to neuro-vascular structures or bone typically
prompt referral for multimodality pre-operative therapy.
Accordingly, given that patients in the NCR and NR
cohorts had significantly larger tumor sizes and were
more likely to undergo periosteal or nerve stripping, the
equivalent local control likely reflects the benefit of
neoadjuvant therapy to SA, but also lessens the likeli-
hood of finding a significant improvement in local con-
trol with neoadjuvant treatment. No patients treated
with IMRT experienced loco-regional recurrence, but no
definitive conclusions can be made with regards to
radiation technique and local failure. IMRT has pre-
viously been demonstrated to result in equivalent or
possibly superior local control compared to conventional
radiation planning [23].
NCR did not improve the R0 resection rate compared
to NR or SA. This finding is similar to a randomized
trial of NR followed by surgery versus surgery with
post-operative radiation [15]. In that study, negative
microscopic margins were seen in 83% of patients trea-
ted with NR and 85% of patients treated with post-
operative radiation, suggesting no difference in surgical
outcome with either strategy [15]. Therefore, as in pre-
vious studies, we are unable to demonstrate an improve-
ment in surgical outcomes with pre-operative therapy.
No improvement in DMFS or OS was detected with
NCR compared to SA or NR. Due to the heterogeneity
of chemotherapy regimens used in this study cohort, we
are unable to determine which, if any, chemotherapy
regimen added to pre-operative radiation is optimal for
impacting DMFS. Additionally, we cannot conclude
which, if any, chemotherapy regimen added to pre-
operative radiation might impact OS. The 5-year OS
          Patients at Risk 
 
 
 
 
 
Time 
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10  20  30  40  50  60  70  80  90 
SA  24  22  14  12  10  7  6  4  4 
NCR  25  15  10  7  6  3  3  3  2 
NR  26  19  18  13  11  9  9  4  2 
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Figure 2 Distant metastasis free survival. Kaplan-Meier plot of 112 Stage II and III extremity soft-tissue sarcoma patients treated with surgery
alone, neoadjuvant chemoradiation, or neoadjuvant radiation alone.
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Page 6 of 11with NCR we found initially appears inferior to other
studies of NCR and NR, in which 5-year OS up to 90%
has been reported [8,24]. However, one analysis reported
OS of 66% at 5 years for patients with tumors measur-
ing 6-10 cm [24]. Therefore, the apparently inferior OS
we observed with NCR compared to other studies likely
is due to selection of higher risk patients with a larger
median tumor size in our cohort. As in previous studies,
addition of radiation to surgery does not appear to
impact OS compared to SA [14,20,25].
We are unable to conclude whether pre-operative
treatment with either NCR or NR improves limb preser-
vation rate. A higher rate of limb amputations among
SA-treated patients was observed compared to the NCR
and NR groups. However, most of these SA-treated
patients were deemed poor limb preservation candidates
at presentation. Therefore, conclusions cannot be made
as to whether a neoadjuvant strategy improved limb pre-
servation. Differences in limb preservation rates between
NCR and NR were not detected, making it unclear if
the addition of chemotherapy to pre-operative therapy
improves limb preservation outcomes. Logistic regres-
sion analysis showed that patients with recurrent disease
treated with limb amputation were not more likely to
have received previous chemotherapy or radiation than
patients undergoing limb preservation for recurrent dis-
ease. Thus, many relapsed patients treated with SA pos-
sibly could have received NCR or NR, but it is likely
that their disease presentation itself precluded functional
limb-preservation.
A possible advantage of pre-operative treatment is the
improvement in OS observed among patients with
extremity STS larger than 5 cm. When compared to SA,
OS was improved significantly both by NCR and NR in
this subset of patients. However, no difference in OS
was found between NCR and NR-treated patients with
extremity STS larger than 5 cm, suggesting that the OS
benefit may be derived mainly from pre-operative radia-
tion therapy rather than from chemotherapy. No rando-
mized controlled trials have compared NCR to SA,
although previous studies failed to demonstrate an OS
benefit when radiation was added to surgery versus SA
[14,20,25]. Thus, the potential OS advantage for patients
with large extremity STS treated pre-operatively, as sug-
gested by our data, is intriguing, and should be con-
firmed prospectively. Caution must be used when
Patients at risk 
Time 
(mos) 
10  20  30  40  50  60  70  80  90 
Primary  19  17  11  10  9  6  5  3  3 
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Figure 3 Distant metastasis free survival. Kaplan-Meier plot of 36 patients treated with surgery alone for primary versus relapsed disease.
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Page 7 of 11interpreting this finding, since only 12 patients with
extremity STS larger than 5 cm were treated with SA.
An inferior DMFS was observed among patients pre-
senting with recurrent disease treated with SA compared
to patients with primary disease treated with SA. This
result suggests that patients presenting with recurrent
extremity STS likely have micrometastases at the time
of relapse. Such patients might benefit from more
aggressive multi-agent chemotherapy either pre- or
post-operatively. An improvement in DMFS for recur-
rent patients given chemotherapy could not be demon-
strated in this analysis, although the exceedingly small
number of relapsed patients (n = 2) treated with NCR
greatly limits our ability to make conclusions about the
value of chemotherapy for improving DMFS in these
patients. Further analyses of outcomes among a higher
number of patients with recurrent disease should be
conducted to determine whether chemotherapy is bene-
ficial in this subgroup of patients.
Potential drawbacks of NCR are increased toxicity and
wound complication rates. In a phase III trial of pre-
versus post-operative radiation without chemotherapy,
wound complications occurred in 35% of patients trea-
ted with pre-operative radiation therapy [15]. While
wound complication rates of just 7.5% have been
reported with intra-arterial doxorubicin and radiation in
single institution experience [13], a multi-center trial of
intra-arterial doxorubicin with radiation reported a 41%
wound complication rate [9]. Logistic regression analysis
did not find a significant association between use of
NCR or NR and wound complications, nor with use of
IOERT/perioperative brachytherapy. Additionally, we
found no significant difference in the wound complica-
tion rate between NCR and NR. We cannot conclude
that NCR worsens the wound complications rate based
on these results. The apparent higher rate of wound
complications we observed may be attributable to differ-
ent definitions of wound complications among studies.
Due to small patient numbers, it is not entirely clear
that the observed rate of wound complications in our
study is significantly different than rates reported in
other studies. Working closely with our plastic surgery
Patients at risk 
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Figure 4 Overall survival. Kaplan-Meier plot of 112 Stage II and III extremity soft-tissue sarcoma patients treated with surgery alone,
neoadjuvant chemoradiation, or neoadjuvant radiation alone.
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impacts on function or quality of life in patients who
experience wound complications. Beyond wound com-
plications, the overall degree of toxicity associated with
NCR appeared higher compared to NR. However, we
were unable to grade toxicities from medical records,
and due to inconsistencies in documentation, the
increased rate of any-toxicity with NCR reported here
must be viewed with caution. Our group is actively pur-
suing further analyses of wound complications in order
to better understand these findings and improve
practice.
There are several limitations to this study. Foremost is
its retrospective nature, which may lead to biased results
Patients at risk 
Time 
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Figure 5 Overall survival. Kaplan-Meier plot of 70 patients with tumors greater than 5 cm treated with surgery alone, neoadjuvant
chemoradiation, or neoadjuvant radiation alone.
Table 3 Treatment outcomes with regard to overall survival, disease relapse (local, distant) and limb preservation by
treatment method and disease presentation among 112 Stage II/III extremity soft-tissue sarcoma cases
Treatment/Disease
Presentation
No.
Pts
Survival
Median (mos)
Overall Survival (%) Local recurrence (%) Distant Metastases (%) Limb Preserved
3-yr 5-yr P No (%) 3-yr p No. (%) 3-yr P No. (%) P
SA 36 41.9 59 34 4 (11) 84 6 (17) 83 22 (61)
Primary 23 51.9 68 35 0.23 1 (4) 95 0.02 2 (9) 94 0.03 18 (78) 0.005
Recurrent 13 24.3 39 39 3 (23) 47 4 (31) 60 4 (31)
NR 37 74.4 67 57 4 (11) 88 11 (30) 68 1 (3)
Primary 31 74.3 67 61 0.75 2 (6) 94 0.006 9 (29) 71 0.63 29 (94) 0.54
Recurrent 6 37.4 67 * 2 (33) 56 2 (33) 50 6 (100)
NCR
¶ 39 * 73 59 4 (10) 85 13 (34) 58 34 (87)
SA, surgery alone; NR, neoadjuvant radiation alone; NCR - neoadjuvant chemoradiation; *, not reached; ¶, only 2 patients in NCR group had recurrent disease and
have not developed local recurrence, distant metastases and were living at time of analysis.
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being compared. Secondly, we studied a diverse mixture
of patients, with differing primary disease sites, limiting
conclusions as to which primary disease location might
benefit most from neoadjuvant therapy. Furthermore,
any conclusion as to which chemotherapy regimen may
be optimal is limited by the relatively small numbers of
patients were treated over the 11-year period with var-
ious chemotherapy agents and schedules.
Conclusions
Despite the limitations of the methodology, the results
of this study have merit. We conclude that both NCR
and NR result in a low rate of loco-regional relapse,
high rates of limb preservation, and acceptable toxicity.
The improved OS of patients with tumors greater than
5 cm treated with pre-operative therapy (both with NCR
and NR) compared to patients with tumors greater than
5 cm receiving SA is compelling. We continue to track
outcomes of patients treated with weekly cisplatin given
with radiation, but cannot make conclusions about its
effectiveness from the available data at this time.
Wound complications remain an important manage-
ment issue for patients treated with a pre-operative
strategy, but NCR did not significantly increase the risk
of wound complications compared to NR.
In addition to cure, goals of extremity STS therapy
include limb preservation, minimizing treatment-related
toxicity, and maximizing quality of life both during and
after treatment. The results of this analysis suggest that
NCR and NR appear to be effective strategies for Stage
II and III STS, perhaps with improved outcomes com-
pared to SA, but NCR is not clearly superior to NR.
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